Cargando…
Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation
BACKGROUND: Serum neurofilament light chain concentration is a proposed biomarker of axonal injury in multiple sclerosis. Mesenchymal stem cells have anti-inflammatory and repair-promoting activities, making them of interest for potential multiple sclerosis treatment. OBJECTIVES: The purpose of this...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831979/ https://www.ncbi.nlm.nih.gov/pubmed/31723439 http://dx.doi.org/10.1177/2055217319887198 |
_version_ | 1783466090275274752 |
---|---|
author | Baldassari, Laura E Planchon, Sarah M Bermel, Robert A Nakamura, Kunio Fisher, Elizabeth Feng, Jenny Sakaie, Ken E Ontaneda, Daniel Cohen, Jeffrey A |
author_facet | Baldassari, Laura E Planchon, Sarah M Bermel, Robert A Nakamura, Kunio Fisher, Elizabeth Feng, Jenny Sakaie, Ken E Ontaneda, Daniel Cohen, Jeffrey A |
author_sort | Baldassari, Laura E |
collection | PubMed |
description | BACKGROUND: Serum neurofilament light chain concentration is a proposed biomarker of axonal injury in multiple sclerosis. Mesenchymal stem cells have anti-inflammatory and repair-promoting activities, making them of interest for potential multiple sclerosis treatment. OBJECTIVES: The purpose of this study was to assess correlation of serum neurofilament light chain concentration and measures of multiple sclerosis disease activity/severity, longitudinal stability of serum neurofilament light chain concentration, and treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration. METHODS: Twenty-four multiple sclerosis patients underwent intravenous infusion of autologous mesenchymal stem cells. Clinical assessments, serum collection, and brain magnetic resonance imaging were performed at months –1, 0 (transplant), 1, 3, and 6. Matched control serum was collected once (n = 10). Serum neurofilament light chain concentration was measured by single-molecule array. Serum neurofilament light chain concentration correlations with disease measures were analyzed by Spearman correlations and linear mixed effect models. Pre-post transplant serum neurofilament light chain concentration was compared by Wilcoxon signed rank testing. RESULTS: There were significant (p<0.01) correlations between serum neurofilament light chain concentration and gadolinium-enhancing lesion number (rho = 0.55) and volume (rho = 0.65), and new/enlarging T2 lesions (rho = 0.65). Patients without disease activity had lower fluctuation in serum neurofilament light chain concentration (p = 0.01). Mean pre- versus post-treatment serum neurofilament light chain concentration values were not significantly different. CONCLUSIONS: Serum neurofilament light chain concentration correlated with magnetic resonance imaging measures of disease activity cross sectionally and longitudinally, and was stable in patients without disease activity. There was no clear treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration. |
format | Online Article Text |
id | pubmed-6831979 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-68319792019-11-13 Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation Baldassari, Laura E Planchon, Sarah M Bermel, Robert A Nakamura, Kunio Fisher, Elizabeth Feng, Jenny Sakaie, Ken E Ontaneda, Daniel Cohen, Jeffrey A Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: Serum neurofilament light chain concentration is a proposed biomarker of axonal injury in multiple sclerosis. Mesenchymal stem cells have anti-inflammatory and repair-promoting activities, making them of interest for potential multiple sclerosis treatment. OBJECTIVES: The purpose of this study was to assess correlation of serum neurofilament light chain concentration and measures of multiple sclerosis disease activity/severity, longitudinal stability of serum neurofilament light chain concentration, and treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration. METHODS: Twenty-four multiple sclerosis patients underwent intravenous infusion of autologous mesenchymal stem cells. Clinical assessments, serum collection, and brain magnetic resonance imaging were performed at months –1, 0 (transplant), 1, 3, and 6. Matched control serum was collected once (n = 10). Serum neurofilament light chain concentration was measured by single-molecule array. Serum neurofilament light chain concentration correlations with disease measures were analyzed by Spearman correlations and linear mixed effect models. Pre-post transplant serum neurofilament light chain concentration was compared by Wilcoxon signed rank testing. RESULTS: There were significant (p<0.01) correlations between serum neurofilament light chain concentration and gadolinium-enhancing lesion number (rho = 0.55) and volume (rho = 0.65), and new/enlarging T2 lesions (rho = 0.65). Patients without disease activity had lower fluctuation in serum neurofilament light chain concentration (p = 0.01). Mean pre- versus post-treatment serum neurofilament light chain concentration values were not significantly different. CONCLUSIONS: Serum neurofilament light chain concentration correlated with magnetic resonance imaging measures of disease activity cross sectionally and longitudinally, and was stable in patients without disease activity. There was no clear treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration. SAGE Publications 2019-11-05 /pmc/articles/PMC6831979/ /pubmed/31723439 http://dx.doi.org/10.1177/2055217319887198 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Paper Baldassari, Laura E Planchon, Sarah M Bermel, Robert A Nakamura, Kunio Fisher, Elizabeth Feng, Jenny Sakaie, Ken E Ontaneda, Daniel Cohen, Jeffrey A Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation |
title | Serum neurofilament light chain concentration in a phase 1/2
trial of autologous mesenchymal stem cell
transplantation |
title_full | Serum neurofilament light chain concentration in a phase 1/2
trial of autologous mesenchymal stem cell
transplantation |
title_fullStr | Serum neurofilament light chain concentration in a phase 1/2
trial of autologous mesenchymal stem cell
transplantation |
title_full_unstemmed | Serum neurofilament light chain concentration in a phase 1/2
trial of autologous mesenchymal stem cell
transplantation |
title_short | Serum neurofilament light chain concentration in a phase 1/2
trial of autologous mesenchymal stem cell
transplantation |
title_sort | serum neurofilament light chain concentration in a phase 1/2
trial of autologous mesenchymal stem cell
transplantation |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831979/ https://www.ncbi.nlm.nih.gov/pubmed/31723439 http://dx.doi.org/10.1177/2055217319887198 |
work_keys_str_mv | AT baldassarilaurae serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation AT planchonsarahm serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation AT bermelroberta serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation AT nakamurakunio serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation AT fisherelizabeth serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation AT fengjenny serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation AT sakaiekene serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation AT ontanedadaniel serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation AT cohenjeffreya serumneurofilamentlightchainconcentrationinaphase12trialofautologousmesenchymalstemcelltransplantation |